Enanta Pharmaceuticals (ENTA) EPS (Diluted) Growth (1y) (2013 - 2026)
Powered by 
Analysis
Enanta Pharmaceuticals (ENTA) EPS (Diluted) Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 89.89% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 7.59% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 144.25% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 315.14% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -11.18% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 96.41% |
| 10 | Enanta Pharmaceuticals | 404.93 Mn | 215.43 Mn | - | 21.50% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 21.50% |
| Mar 31, 2026 | 57.49% |
| Dec 31, 2025 | 60.43% |
| Sep 30, 2025 | 35.62% |
| Jun 30, 2025 | 20.17% |
| Mar 31, 2025 | 27.96% |
| Dec 31, 2024 | 33.75% |
| Sep 30, 2024 | -0.96% |
| Jun 30, 2024 | 42.34% |
| Mar 31, 2024 | 17.78% |
| Dec 31, 2023 | -13.77% |
| Sep 30, 2023 | -4.88% |
| Jun 30, 2023 | -21.22% |
| Mar 31, 2023 | -9.52% |
| Dec 31, 2022 | 5.73% |
| Sep 30, 2022 | -5.39% |
| Jun 30, 2022 | -28.71% |
| Mar 31, 2022 | 9.08% |
| Dec 31, 2021 | -256.38% |
| Sep 30, 2021 | 17.59% |